Track topics on Twitter Track topics that are important to you
UK company Prokarium has raised $10 million to develop groundbreaking synthetic biology techniques to create a new generation of vaccines, which could be taken orally, and not have to be kept in a ref...
Prokarium raised $10 million from Korean, Saudi and Swedish investors to advance clinical development of vaccines against chl -More-
UK-based synthetic biology firm Prokarium has secured $10 million from Saudi, Swedish and Korean investors to help drive clinical development of thermostable vaccines.
Synthetic biology firm Prokarium raised $10mm in its Series B financing round led by the Riyadh Valley Co., which was joined by Flerie Invest and Korea Investment Partners.
Prokarium, a UK-based synthetic biology company and developer of Vaxonella, an oral, thermostable vaccine delivery platform, announced the completion of a $10 million investment round
UK-based synthetic biology company, Prokarium, has completed an investment round, raising $10 million for the clinical development of vaccines against chlamydia, C.difficile and enteric fever, plus an...
Prokarium has raised $10M (€8M) from Saudi, Swedish and Korean investors to support the clinical development of its oral vaccines for infectious diseases like typhoid. Since its foundation in 2012, ...
Prokarium, the UK-based synthetic biology company that has developed Vaxonella, an oral, thermostable vaccine delivery platform, today announced the completion of a $10 mil...
We have published hundreds of Prokarium news stories on BioPortfolio along with dozens of Prokarium Clinical Trials and PubMed Articles about Prokarium for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Prokarium Companies in our database. You can also find out about relevant Prokarium Drugs and Medications on this site too.